ESMO 2020 | Ex vivo models of breast cancer

Anna Diana, MD, University of Campania Luigi Vanvitelli, Naples, Italy and UOC Oncologia, Ospedale del Mare, Naples, Italy, discusses efficacy of the triple combination of estrogen receptor (ER), CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer. Results showed an encouraging activity of the triple combination of ER, CDK4/6, and PI3K pathway inhibitors in ex vivo models of ER-positive breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).